Investors
A MESSAGE FROM OUR CEO
”We are confident resomelagon has incredible potential for early intervention in patients with severe RA, so progressing with ADVANCE is top priority.”
-
October 18, 2024 Non RegulatorySynAct Pharma to attend BIO-Europe in Stockholm November 4-6
-
September 23, 2024 Non RegulatorySynAct initiates the Phase 2b ADVANCE study with resomelagon (AP1189) in the US
-
September 13, 2024 Non RegulatorySynAct Pharma to present clinical data on resomelagon (AP1189) at ACR Convergence
The interim report for Q2 2024 was published on August 20, 2024, at 07.30 CEST.